7:05 PM
 | 
May 12, 2014
 |  BC Extra  |  Clinical News

Gene Signal publishes mixed data for aganirsen

Data published in Ophthalmology showed that twice-daily aganirsen ( GS-101) eye drops from Gene Signal International S.A. (Lausanne, Switzerland) missed the primary endpoint of improving absolute mean visual acuity value from...

Read the full 146 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >